Regulus Reports First Quarter 2017 Financial Results and Corporate Restructuring
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips below $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Regulus Therapeutics (RGLS) Misses Q1 EPS by 3c, Announces Workforce Reduction; CEO to Resign
May 4, 2017 4:33 PM EDTRegulus Therapeutics (NASDAQ: RGLS) reported Q1 EPS of ($0.38), $0.03 worse than the analyst estimate of ($0.35).
The Company also announced a corporate restructuring plan to streamline its operations as it focuses on its most promising discovery and development programs.
The restructuring includes an immediate workforce reduction of approximately 30%, which is expected to result in approximately $6.0 million in annual... More
